Dr. Steven M. Paul to Retire from Lilly as Executive Vice President, Science and Technology, President, Lilly Research Laboratories; Dr. Jan M. Lundberg, Executive Vice President, Head of Global Disco

Indianapolis, November 13 (ots/PRNewswire) -

Eli Lilly and Company (NYSE: LLY) announced today that Steven M.
Paul, M.D., executive vice president, science and technology, and
president, Lilly Research Laboratories, will retire from Lilly
effective February 28, 2010. Lilly has also announced that Jan M.
Lundberg, Ph.D., executive vice president and head of global
discovery research, AstraZeneca, is to become his successor. Paul is
committed to working closely with Lundberg to ensure a successful
transition. Lundberg plans to join Lilly in Indianapolis as early as
January 2010, subject to completion of the U.S. immigration process.

Paul joined Lilly as vice president, central nervous system
discovery research and decision-phase medical research, in 1993. He
was named group vice president, therapeutic area discovery research
and clinical investigation, in 1998. Paul has been in his current
role since 2003. Before coming to Lilly, Paul was the scientific
director of the National Institute of Mental Health.

"Under Steve's leadership, we now have the most robust pipeline
in Lilly's history, including approximately 60 unique potential
medicines-both small molecules and biologics-in human testing.
Additionally, Steve has helped to recruit many of the top leaders we
have in LRL today. Steve has also been actively involved in advancing
Lilly's research in the area of Alzheimer's disease, including
solanezumab, one of Lilly's two late-stage Alzheimer's molecules,"
said John Lechleiter, Ph.D., Lilly chairman and chief executive
officer.

"Steve has also been instrumental in successfully transforming
R&D over the past several years, including the implementation of the
FIPNet model, moving Lilly from a fully integrated pharmaceutical
company, where we previously owned all aspects of the value chain, to
a fully integrated pharmaceutical network, where we are playing
bigger than our size. He has also been a tremendous ambassador for
the company, representing Lilly through his involvement with
biopharmaceutical industry, scientific, and medical organizations,"
added Lechleiter.

Paul had planned to retire in 2010. With the successful
recruitment of his successor, he will retire at the end of February
2010.

"Advancing our pipeline to patients as quickly and as safely as
possible is the biggest challenge Lilly faces in 2010 and beyond. We
are confident that Dr. Lundberg will be able to deliver on this
challenge," said Lechleiter.

Lundberg has a Ph.D. from Sweden's world-renowned Karolinska
Institute, where he was a professor in the department of pharmacology
before moving to industry. Prior to Karolinska, he attended Gustavus
Adolphus College in Minnesota and the University of Gothenburg in
Sweden. He has published approximately 500 scientific articles,
mainly related to mechanisms of cell signaling in the nervous,
cardiovascular, endocrine and respiratory systems. Lundberg has won a
variety of research awards and is a highly cited author in the areas
of biology and biochemistry, pharmacology and neuroscience. He has
been a member of the Swedish Medical Research Council and also of the
Advisory Board for Drug Approvals at the Swedish Medical Product
Agency. In January 2003, he was appointed Honorary Doctor of Pharmacy
at Uppsala University.

During the last 10 years at AstraZeneca, as head of global
discovery research, Lundberg was instrumental in delivering more than
150 drug candidates to the company's pipeline. He had responsibility
for discovery research and supported clinical development of
potential therapies for cancer, infection, central nervous system
disorders, pain, cardiovascular, metabolic and respiratory diseases,
gastrointestinal conditions, and inflammation. Lundberg was also
responsible for discovery-enabling technologies, discovery
informatics, drug metabolism and pharmacokinetics, translational
science and safety assessment. He has had a leading role in external
activities, including in-licensing of projects and technologies, as
well as acquisitions of biotech companies. His organization was
involved with both small molecules and biologics. For the past seven
years, he has been an executive vice president and member of the
senior executive team, reporting to the CEO of AstraZeneca.

"I have always had tremendous respect for the quality of people,
science and products at Lilly. Therefore, I feel honored to be the
successor to Steve Paul. I'm really looking forward to meeting my
colleagues at Lilly and together with them conquering the future
challenges and advancing innovative medicines that meet the needs of
patients, payers and prescribers," said Lundberg.

According to Paul, "Jan possesses the right mix of scientific
expertise and industry experience needed to advance the innovative
pipeline of this company."

About Lilly

Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of pharmaceutical products by applying the latest
research from its own worldwide laboratories and from collaborations
with eminent scientific organizations. Headquartered in Indianapolis,
Ind., Lilly provides answers - through medicines and information -
for some of the world's most urgent medical needs. Additional
information about Lilly is available at www.lilly.com.

C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

ots Originaltext: Eli Lilly and Company
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Christine Van Marter, Eli Lilly and Company, +1-317-651-1473